In its initial public offering which has just been completed, Celon Pharma acquired the anticipated gross PLN 245 million. It is so far the largest initial public offering on the Polish capital market in 2016. Celon Pharma S.A. will therefore be the first comprehensive biopharmaceutical company which manufactures specialised therapies and at the same time has a broad pipeline of innovative projects to be listed on the Polish stock exchange.
The public offering covered 15,000,000 newly issued B series shares, including 13,000,000 shares in the Institutional Investor Tranche and 2,000,000 shares in the Individual Investor Tranche. After subscriptions have been closed, the company acquired gross funds amounting to approx. PLN 245 million which will be used to finance selected projects related to the implementation of the Company’s development strategy both in the field of generic drugs and innovative projects. Shareholders have acquired, by way of the public offering, only approx. 33% of the Company capital, which corresponds to a 25% share of votes at the General Shareholder’s Meeting. The majority shareholder and President of the Management Board remains Maciej Wieczorek, PhD, and the entity responsible for the development of the Company’s development strategy and main decision maker – the Management Board, whose composition remains unchanged.
Maciej Wieczorek: President of the Management Board of Celon Pharma S.A.: “We have experience, competence and a clear vision for the future. What we needed was fuel which would speed up the implementation of our ambitious plans connected with expansion of our products abroad and development of innovative projects. The IPO and our debut on the stock exchange is an element of our long-term plan, the foundations of which we have been building from the beginning of the Company’s operation. Our business model is effective and has been yielding good results for many years. Our ultimate goal is to develop and manufacture specialised prescription drugs which are the answer to unmet clinical needs.”
The success of offering is evidenced by the fact that investors expressed their willingness to purchase the Company’s shares for more than PLN 1.5 billion, including in the retail tranche almost 2.5 thousand investors offered to buy shares with the value of over PLN 180 million. Mercurius Dom Maklerski was the Offerer.
“Investors were very enthusiastic about our Company’s strategy and large numbers of them declared their willingness to buy the shares. It is also important in view of the fact that we are dealing with rather uncertain conditions in the capital market. This makes us even more satisfied with the success of our IPO”. says Maciej Wieczorek, President of the Management Board of Celon Pharma S.A.
Celon Pharma S.A. will be the first biopharmaceutical company which at the same time specialises in developing, manufacturing and marketing of specialised generic drugs, as well as conducting research on innovative therapies to be listed on the Warsaw Stock Exchange. The Company’s current product portfolio can be divided into standard generic drugs, combination generic drugs, and designs of new drugs, including potential innovative drugs. Celon Pharma S.A. has two fully equipped laboratories dedicated to research and development of medicinal products (R&D) for both generic and innovative drugs. It also has a modern manufacturing facility in Kazun Nowy where dry pharmaceutical forms are manufactured.
